Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients

Spinal Cord

Volumn 38, Issue 4, 2000, Pages 250-254

  Haferkamp, A ^a   Staehler, G ^a   Gerner, H J ^a   Dorsam J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anticholinergics; Neurogenic bladder; Urodynamics

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN;

ADOLESCENT; ADULT; ARTICLE; BLADDER CAPACITY; BLADDER PRESSURE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINENCE; DETRUSOR MUSCLE; DRUG FORMULATION; FEMALE; HUMAN; HYPERREFLEXIA; MALE; NEUROGENIC BLADDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; URODYNAMICS; XEROSTOMIA;

EID: 0034110473     PISSN: 13624393     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.sc.3100995     Document Type: Article

References (21)

1. 1 Guttmann L, Frankel H. The value of intermittent catheterization in the early management of traumatic paraplegia and tetraplegia. Paraplegia 1966; 4: 63-84.
2. 2 Lapides J, Diokno AC, Silber SJ, Lowe BS. Clean, intermittent self-catheterization in the treatment of urinary tract disease. J Urol 1972; 107: 458.
3. 3 McGuire EJ, Woodside JR. Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol 1981; 126: 205.
4. 4 Spindel MR et al. The changing neurourologic lesion in myelodysplasia. JAMA 1987; 258: 1630.
5. 5 Buyse G, Verpoorten C, Vereecken R, Casaer P. Treatment of neurogenic bladder disfunction in infants and children with neurospinal dysraphism with clean intermittent catheterization and optimized intravesical Oxybutynin hydrochloride therapy. Eur J Ped Surg 1985; 5 (Suppl. 1) 31-34.
6. 6 Brendler CB, Radebaugh LC, Mohler JL. Topical oxybutynin chloride for relaxation of dysfunctional bladders. J Urol 1989; 141: 1350-1351.
7. 7 Moisey CU, Stephenson TP, Brendler CB. The urodynamic and subjective results of treatment of detrusor instability with oxybutynin chloride. Brit J Urol 1980; 52: 472.
8. 8 Thüroff JW et al. Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity. Oxybutynin versus propantheline versus placebo. J Urol 1991; 145: 813-17.
9. 9 Madersbacher H, Knoll M. Intravesical application of Oxybutynin. Mode of action in controlling detrusor hyperreflexia. Eur Urol 1995; 28: 340-344.
10. 10 Autret E et al. Plasma levels of oxybutynin chloride in children. Eur J Clin Pharmacol 1994; 46: 83-85.
11. 11 Greenfield SP, Fera M. The use of intravesical Oxybutynin chloride in children with neurogenic bladder. J Urol 1991; 146: 532-534.
12. 12 Kaplinsky R, Greenfield S, Wan J, Fera M. Expanded follow up of intravesical Oxybutynin chloride use in children with neurogenic bladder. J Urol 1996; 156: 753-756.
13. 13 Abrams P, Blaivas JG, Stanton SL, Anderson JT. The standardisation of teminology of lower urinary tract function. Scand J Urol Nephrol 1988; 114: 5-19.
14. 14 Berger RM et al. Bladder capacity (ounces) equals age (years) plus 2 predicts normal bladder capacity and aids in diagnosis of abnormal voiding patterns. J Urol 1983; 129: 347.
15. 15 Köhler W, Schachtel G, Voleske P. Eine Auswahl wichtiger Tests. In: Biostatistik. 2nd edn, p103, Springer Heidelberg: Germany, 1995.
16. 16 SAS Procedure Guide. Version 6, 3rd edn, Cary: NC, 1990.
17. 17 Massad CA, Kogan BA, Trigo-Rocha FE. The pharmacokinetics of intravesical and oral oxybutynin chloride. J Urol 1992; 148: 595-597.
18. 18 Amark P et al. Pharmacokinetics and effects of intravesical Oxybutynin on the paediatric neurogenic bladder. Br J Urol 1998; 82: 859-864.
19. 19 Prasad KVR, Vaidyanathan S. Intravesical Oxybutynin chloride and clean intermittent catherization in patients with neurogenic vesical dysfunction and decreased bladder capacity. Br J Urol 1993; 72:719-722.
20. 20 Palmer LS, Zebold K, Firlit CF, Kaplan WE. Complications of intravesical Oxybutynin chloride therapy in the pediatric myelomeningocele population. J Urol 1997; 157: 638-640.
21. 21 Mizunaga M et al. Intravesical instillation of Oxybutynin hydrochloride, therapy for patients with a neuropathic bladder. Paraplegia 1994; 342: 25-29.